Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16350310 | 0.91 | MEN1 (0.53) | MEN1KMT2ACNR1GLP1RCA1 | |
| SCHEMBL13857334 | 0.89 | MEN1 (0.54) | MEN1KMT2AZDHHC7CNR1 | |
| SCHEMBL13635152 | 0.89 | SIRT6 (0.59) | MEN1KMT2AGLP1RSIRT6SIRT1 | |
| SCHEMBL12706032 | 0.87 | MEN1 (0.49) | MEN1KMT2ACNR1GLP1RCA1 | |
| SCHEMBL12705941 | 0.87 | EPHX1 (0.50) | MEN1KMT2ACNR1GLP1RCA1 | |
| SCHEMBL12737485 | 0.84 | MEN1 (0.51) | MEN1KMT2ACNR1GLP1RCA1 | |
| SCHEMBL26034698 | 0.84 | MEN1 (0.51) | MEN1KMT2ACNR1GLP1RTLR2 | |
| SCHEMBL25921498 | 0.83 | MEN1 (0.47) | MEN1KMT2ACNR1GLP1RTLR2 | |
| SCHEMBL12706042 | 0.82 | MEN1 (0.46) | MEN1KMT2ACNR1GLP1RCA1 | |
| SCHEMBL22802925 | 0.81 | CES2 (0.50) | MEN1KMT2AZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729030-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130130979-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8324159-B2 | Erythropoietin receptor peptide formulations and uses | AFFYMAX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8304391-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20110245176-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-7919461-B2 | Utilizing amino acid sequences linked to polyethylene glycol as agonists; increasing red blood cell production; chronic kidney disease | AFFYMAX, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7906485-B2 | Erythropoietin receptor peptide formulations and uses | AFFYMAX, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7855175-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090227508-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090209457-A1 | TREATMENT OF ANTI-ERYTHROPOIETIN ANTIBODY-MEDIATED DISORDERS WITH SYNTHETIC PEPTIDE-BASED EPO RECEPTOR AGONISTS | AFFYMAX, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090136442-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | AFFYMAX, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090118183-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | AFFYMAX, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090048166-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | AFFYMAX, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080081783-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | AFFYMAX, INC. (US) | 2008-04-03 | — | — | US | disclosed |
| US-20070104704-A1 | Erythropoietin receptor peptide formulations and uses | AFFYMAX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118183-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | EPOR, PROKR1, PROKR2 | MEN1 2467/4885KMT2A 3618/4885ZDHHC7 2101/4885 |
| US-20090048166-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | MEN1 3831/4885KMT2A 4517/4885ZDHHC7 2730/4885 |
| US-20090136442-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | EPOR, PROKR1, PROKR2 | MEN1 2467/4885KMT2A 3618/4885ZDHHC7 2101/4885 |
| US-20110245176-A1 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | MEN1 3831/4885KMT2A 4517/4885ZDHHC7 2730/4885 |
| US-20090227508-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | MEN1 3427/4885KMT2A 4254/4885ZDHHC7 2644/4885 |
| US-20130130979-A1 | PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR | EPOR, PROKR1, EDNRB | MEN1 3427/4885KMT2A 4254/4885ZDHHC7 2644/4885 |
| US-20080081783-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | EPOR, PROKR1, PROKR2 | MEN1 2467/4885KMT2A 3618/4885ZDHHC7 2101/4885 |
| US-20070104704-A1 | Erythropoietin receptor peptide formulations and uses | EPOR, PROKR1, PROKR2 | MEN1 2467/4885KMT2A 3618/4885ZDHHC7 2101/4885 |
| US-20090209457-A1 | TREATMENT OF ANTI-ERYTHROPOIETIN ANTIBODY-MEDIATED DISORDERS WITH SYNTHETIC PEPTIDE-BASED EPO RECEPTOR AGONISTS | EPOR, PROKR1, MPL | MEN1 1069/4885KMT2A 757/4885ZDHHC7 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.